Adenosine receptors in neurological disorders

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 5, 2000, Pages 635-664

  Impagnatiello, Francesco ^a   Bastia, Elena ^a   Ongini, Ennio ^a   Monopoli, Angela ^a  

^a Schering Plough Research Institute   (Italy)

Author keywords

adenosine; adenosine receptors; CNS; neurological disorders

Indexed keywords

EID: 0001524498     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.5.635     Document Type: Review

References (165)

1. OLAH M, STILES GL: The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther. (2000) 85:55-75.
2. ONGINI E, SCHUBERT P: Neuroprotection induced by stimulating A1 or blocking A2Aadenosine receptors: an apparent paradox. DrugDev. Res. (1998) 45:387-393.
3. WEISNER J, UGARKAR BG, CASTELLINO AJ et al.: Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J. Pharmacol. Exp. Ther. (1999) 289:1669-1677.
4. ADAMI M, BERTORELLI R, FERRI N, FODDI MC, ONGINI E: Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur. J. Pharmacol. (1995) 294:383-389.
5. SAWYNOK J: Adenosine receptor activation and nociception. Eur. J. Pharmacol. (1998) 317:1-11.
6. SATOH S, MATSUMARA H, KOIKE N, TOKUNAGA Y, MAEDA T, HAYAISHI O, Region-dependent difference in the sleep-promoting potency of an adenosine A2A receptor agonist. Eur. J. Neurosci. (1999) 11:1587-1597.
7. ONGINI E, FREDHOLM BB: Pharmacology of adenosine A2A receptors. Trends Pharmacol. Sci. (1996) 17:364-372.
8. RICHARSON PJ, KASE H, JENNER PG: Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. (1997) 18:338-344.
9. LEDENT C, VAUGEOIS JM, SCHIFFMANN SN, PEDRAZZINI T et al: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature (1997) 388:674-678.
10. CHEN JF, HUANG Z, MA J et al: A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. (1999) 19:9192-9200.
11. SALVATORE CA, TILLEY SL, LATOUR AM, FLETCHER DS, KOLLER BH, JACOBSON MA: Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. (2000) 275:4429-4434.
12. JOHANSSON B, FREDHOLM BB, HEERLENIUS E et al: Altered synaptic transmission, reduced hypoxia response and hyperalgesia in adenosine A1 knockout mice. 30th Annual Meeting Society of Neuroscience. New Orleans, Louisiana, USA (2000).
13. MATHERNE GP, LINDEN J, BYFORD AM, GAUTHIER NS, HEADRICK JP: Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc. Natl. Acad. Sci. USA (1997) 94:6541-6546.
14. CALABRESI P, CENTONZE D, PISANI A, BERNARDI G: Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. J. Neurosci. (1997) 17:4509-4516.
15. FERRE' S, FREDHOLM BB, MORELLI M, POPOLI P, FUXE K: Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. (1997) 20:482-487.
16. DIXON AK, GUBITZ AK, SIRINATHSINGHJI DJS, RICHARDSON PJ, FREEMAN TC: Tissue distribution of adenosine receptor mRNAs in the rat. Br J. Pharmacol (1996) 118:1461-1468.
17. SVENNINGSSON P, HALL H, SEDVALL G, FREDHOLM BB: Distribution of adenosine receptors in the post-mortem human brain. An extended autoradiographic study. Synapse (1997) 27:322-335.
18. GILCHRIST A, MAZZONI MR, DINEEN B et al: Antagonists of receptor-G protein interface block Gi-coupled signal transduction. J. Biol. Chem. (1998) 273:14912-14919.
19. MEI YA, LE FOLL F, VAUDRY H, CAZIN L: Adenosine inhibits L-and N-type calcium channels in pituitary melanotrophs. Evidence for the involvement of a G protein in calcium channel gating. J. Neuroendocrinol. (1996) 8:85-91.
20. BIBER K, KLOTZ KN, BERGER M, GEBICKE-HERBER PJ, VAN CALKER D: Adenosine A1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J. Neurosci. (1997) 17(13):4956-4964.
21. AKBAR M, OKAJIMA F, TOMURA H, SHIMEGI S, KONDO, Y: A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipaseCand arachidonate release. Mol. Pharmacol. (1994) 45:1036-1042.
22. JACOBSON KA, VAN GALEN PJM, WILLIAMS M: Adenosine receptors: pharmacology, structure-activity relationship and therapeutic potential. J. Med. Chem. (1992) 35:407-422.
23. KLOTZ KN, HESSLING J, HEGLER J et al.: Comparative pharmacology of human adenosine receptor subtype-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. (1998) 357:1-9.
24. ZOCCHI C, ONGINI E, FERRARA S, BARALDI PG, DIONISOTTI S: Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br. J. Pharmacol. (1996) 117:1381-1386.
25. DIONISOTTI S, ONGINI E, ZOCCHI C, KULL B, ARSLAN G, FREDHOLM BB: Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br. J. Pharmacol. (1997) 121:353-360.
26. SALVATORE CA, JACOBSON MA, TAYLOR HE, LINDEN J, JOHNSON RG: Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1993) 90:10365-10369.
27. VARANI K, CACCIARI B, BARALDI PG, DIONISOTTI S, ONGINI E, BOREA PA: Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors. Life Sci. (1998) 63:81-87.
28. VARANI K, MERIGHI S, GESSI S et al.: [3H]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol. Pharmacol.(2000) 57:968-975.
29. SHIMADA J, KOIKE N, NONAKA H et al.: Adenosine A2A antagonist with potent anticataleptic activity. Bioorg. Med. Chem. (1997) 7:2349-2352.
30. MARSTON HM, FINLAYSON K, MAEMOTO T et al.: Pharmacological characterization of a simple behavioural response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques. J. Pharmacol. Exp. Ther. (1998) 285:1023-1030.
31. EL YACOUBI M, LEDENT C, MENARD JF, PARMENTIER M, COSTENTIN J, VAUGEOIS JM: The stimulant effects of caffeine onlocomotor behaviourinmice are mediated through its blockade of adenosine A2A receptors. Br. J. Pharmacol. (2000) 129:1465-1473.
32. FLORIO C, ROSATI AM, TRAVERSA U, VERTUA R: Inhibi- toryandexcitatoryeffectsofadenosineantagonists on spontaneous locomotor activity in mice. Life Sci. (1997) 60:1477-1486.
33. COMMISSARISR L, MCCLOSKEY TC, DAMIANG M, BROWN BD, BARRACO RA, ALTMAN HJ: Antagonism of the anti-conflict effects of phenobarbital, but not diazepam, by the A1 adenosine agonist L-PIA. Psycho-pharmacology (1990) 102:283-290.
34. JAIN N,KEMP N,ADEYEM OO,BUCHANAN P,STONE TW: Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. (1995) 116:2127-2133.
35. FLORIO C, PREZIOSO A, PAPAIOANNOU A, VERTUA R: Adenosine A1receptors modulate anxietyinCD1mice. Psychopharmacology (1998) 136:311-319.
36. HARAGUCHI H, KURIBARA H: Behavioural effects of adenosine agonists: evaluation by punishment, discrete shuttle avoidance and activity tests in mice. Jpn. J. Pharmacol. (1991) 55:303-310.
37. KUROKAWA M, KOGA K, KASE H, NAKAMYRA J, KUWANA Y: Adenosine A2Areceptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. (1996) 66:1882-1888.
38. CONSTENLA AR, DE MENDONCA A, RIBEIRO JA: Adenosine modulates synaptic plasticity in hippocampus slices from aged rats. Brain Res. (1999) 851:228-234.
39. KEMP N, BASHIR ZI: A role for adenosine in the regulation of long-term depression in the adult rat hippocampusin vitro. Neurosci. Lett. (1997) 225:189-192
40. VON LUBITZ DKJE, PAUL IA, CARTER MF, JACOBSON KA: Effects of N6-cyclopentyladenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice. Eur. J. Pharmacol. (1993) 249:265-270.
41. SUZUKI F, SHIMADA J, SHIOZAKI S et al.: Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine-or N6-[(R)-phenyl-isopropyl]adenosine-induced cognitive disturbance. J. Med. Chem. (1993) 36:2508-2518.
42. ZHANG G,FRANKLIN PH, MURRAY TF: Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J. Pharmacol. Exp. Ther. (1993) 264:1415-1424.
43. YOUNG D, DRAGUNOW M: Status epilepticus may be caused by loss of adenosine anticonvulsant mechanism. Neuroscience (1994) 58:245-261.
44. PAGONOPOULOU O, ANGELATOU F: Time development and regional distribution of [3H]nitrobenzyl-thioinosine adenosine uptake site binding in the mouse brain after acute pentylenetetrazol-induced seizures. J. Neurosci. Res. (1998) 53:433-442.
45. DE SARRO GB, DE SARRO A, DONATO DI PAOLA E, BERTORELLI R: Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur. J. Pharmacol. (1999) 371:137-145.
46. EKONOMOU A, SPERK G, KOSTOPOULOS G, ANGELATOU F: Reduction of A1 adenosine receptors in rat hippocampus after kainic-acid induced limbic seizures. Neurosci. Lett. (2000) 284:49-52.
47. RUDOLPHI KA, SCHUBERT P, PARKINSON FE, FREDHOLM BB: Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol. Sci. (1992) 13:439-445.
48. LOGAN M, SWEENEY ML: Adenosine A1 receptor activation preferentially protects cultured cerebellar neurons astrocytes against hypoxia-induced death. Mol. Chem. Neuropathol. (1997) 31:119-133.
49. VON LUBITZ DK: Adenosine and cerebral ischaemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. (1999) 371:85-102.
50. VON LUBITZ DKJE, DAMBROSIA JM, REDMON DJ: Protective effect of cyclohexyl adenosine in treatment of cerebral ischemia in gerbils. Neuroscience (1989) 2:451-457.
51. PHILLIS JW: The effectsofselective A1 and A2 adenosine receptor antagonists on cerebral ischaemic injury in the gerbil. Brain Res. (1995) 705:79-84.
52. BONA E,ADEN U,GILLAND E,FREDHOLM BB, HAGBERG H: Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology (1997) 36 1327-1338.
53. ARVIN B, NEVILLE NF, PAN J, ROBERTS PJ: 2-Chloroadenosine attenuates kainic acid induced toxicity within the rat striatum: relationship to release of glutamate and calcium influx. Br. J. Pharmacol. (1989) 98:225-253.
54. MACGREGOR DG, MILLER DW, STONE TW: Mediation of neuroprotective action of R-phenylisopropyladen-osine through a centrally located adenosine A1 receptor. Br. J. Pharmacol. (1993) 110:470-476.
55. KOWALUK EA, KOHLHAAS KL, BANNON A, GUNTHER K, LYNCH JJ, JARVIS MF: Characterization of the effects of adenosine kinaseinhibitorsonacutethermal nocicep-tioninmice. Pharmacol. Biochem. Behav. (1999)63:83-91.
56. CUI JG, SOLLEVI A, LINDEROTH B, MEYERSON BA: Adenosine receptor activation suppresses tactile hypersensitivity and potentiates spinal cord stimulation in mononeuropathic rats. Neurosci. Lett. (1997) 223 173-176.
57. VON HEIJNE M, HAO JX, SOLLEVI A, XU XJ: Intrathecal adenosine does not relieve allodynia-like behavior in spinally injured rats. NeuroReport (1999) 10:3247-3251.
58. SEGERDAHL M, EKBLOM A, SIOLUND KF, BELFRAGE M, FORSBERG C, SOLLEVI A: Systemic adenosine attenuates touch evoked allodynia induced by mustard oil in humans. NeuroReport (1995) 6:753-756.
59. KOWALUK EA, YU H, MIKUSA J et al.: ABT-702, a novel orally effective adenosine kinase (AK) inhibitor analgesic with antiinflammatory properties. Drug Dev. Res. (2000) 50:104.
60. LEE C, JIANG M, BHAGWAT S et al: Structure-activity relationship of a series of novel, non-nucleoside analogs as adenosine kinase inhibitors. DrugDev. Res. (2000) 50:62.
61. LEE YW, YAKSH TL: Pharmacology of the spinal adenosine receptor which mediates the antiallodynic action of intrathecal adenosine agonists.J. Pharmacol Exp. Ther. (1996) 277:1642-1648.
62. LINDSAY EA, MORRIS MA, GOS A et al.: Schizophrenia and chromosomal deletions within 22q11.2. Am. J. Hum. Genet. (1995) 56:1502-1503.
63. PALMER TM, JACOBSON KA, STILES GL: Immunological identification of A2 adenosine receptors by two antipeptide antibody preparations. Mol Pharmacol (1992) 42:391-397.
64. RIBEIRO JA: Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators.Eur.J.Pharmacol (1999) 375:101-113.
65. ASKALAN R, RICHARDSON PJ: Role of histidine residues in the adenosine A2A receptor ligand binding site. J. Neurochem. (1994) 63:1477-1484.
66. JOHANSSON B, FREDHOLM BB: Further characteriza tion of the binding of the adenosine receptor agonist, [3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology (1995) 34:393-403.
67. ROSIN DL, ROBEVA A, WOODARD RL, GUYENET PG, LINDEN J: Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system.J. Comp. Neurol (1998) 401:163-186.
68. SVENNINGSSON P, LE MOINE C, FISONE G, FREDHOLM BB: Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol (1999) 59:355-396.
69. FINK JS, WEAVER DR, RIVKEES SA et al: Molecular cloning of the rat A2A adenosine receptor; selective co-expression with D2 dopamine receptors in rat striatum. Mol Brain Res. (1992) 14:186-195.
70. SVENNINGSSON P, LE MOINE C, KULL B, SUNAHARA R, BLOCH B, FREDHOLM BB: Cellular expression of adenosine A2A receptor mRNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience (1997) 80:1171-1185.
71. SONG WJ, TKATCH T, SURMEIERD J: Adenosine receptor expression and modulation of Ca2+ channels in rat striatal cholinergic interneurons. J. Neurophysiol (2000) 83:322-332.
72. PRESTON Z, LEE K, WIDDOWSON L, FREEMAN TC, DIXON AK, RICHARDSON PJ: Adenosine receptor expression and function in rat striatal cholinergic interneurons. Br. J. Pharmacol (2000) 130(4):886-90.
73. CUNHA RA, COSTANTINO MD, RIBEIRO JA: G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that adenosine A1 and striatal A2A receptors. Naunyn-Schmiedberg's Arch. Pharmacol. (1999) 51:199-206.
74. KAELIN-LANG A, LAUTERBURG T, BURGUNDER JM: Expression of adenosine A2A receptors gene in the olfactory bulb and spinal cord of rat and mouse. Neurosci. Lett. (1999) 261:189-191.
75. WEAVER DR: A2A adenosine receptor gene expression in developing rat brain. Brain Res. Mol. Brain Res. (1993) 20:313-327.
76. JOHANSSON B, GEORGIEV V, FREDHOLM BB: Distribution and postnatal ontogeny of adenosine A2A receptors in rat brain: comparison with dopamine receptors. Neuroscience (1997) 80:1187-1207.
77. ARSLAN G, KULL B, FREDHOLM BB: Signaling via A2A adenosine receptors in four PC 12 cell clones. Naunyn-Schmiedeberg's Arch. Pharmacol. (1999) 359:28-32.
78. LINDSKOG M, SVENNINGSSON P, FREDHOLM BB, GREENGARD P, FISONE G: Activation of dopamine D2 receptor decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neuron via different mechanism. Neuroscience (1999) 88:1005-1008.
79. FIENBERG AA, GREENGARD P: The DARPP-32 knockout mouse. Brain Res. Brain Res. Rev. (2000) 31:313-319.
80. BIBB JA, SNYDER GL, NISHI A etal: Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature (1999) 402:669-671.
81. GONCALVES ML, CUNHA RA, RIBEIRO JA: Adenosine A2A receptors facilitate 45 Ca2+ uptake through class A calcium channels in rat hippocampal CA3 but not CA1 synaptosomes. Neurosci. Lett. (1997) 238:73-77.
82. GUBIYZ AK, WIDDOWSON L, KUROKAWA M, KIRKPATRICK KA, RICHARDSON PJ: Dual signalling by the adenosine A2Areceptor involves activation of both N-and P-type calcium channels by different Gproteins and protein kinases in the same striatal nerve terminals. J. Neurochem. (1996) 67:374-381.
83. DIXON AK, WIDDOWSON L, RICHARDSON PJ: Desensiti-zation of adenosine A1 receptor by the A2A receptor in the rat striatum. J. Neurochem. (1997) 69:315-321.
84. FUXE K, FERRE S, ZOLI M, AGNATI L: Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Rev. (1998) 26:258-273.
85. JIN S, JOHANSSON B, FREDHOLM BB: Effects of adenosine A1 and A2A receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J. Pharmacol. Exp. Ther. (1993) 267:801-808.
86. SVENNINGSSON P, NERGARDH R, FREDHOLM BB: Regional differences in the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA expression in the rat. Neuropharmacology (1998) 37:331-337.
87. KULL B, ARSLAN G, NILSSON C, LORENZON A, SCHWABE U, FREDHOLM BB: Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem. Pharmacol. (1999) VOL57:65-75.
88. KULL B, FERRE' S, ARLSAN G etal: Reciprocal interactions between adenosine A2A and dopamine D2 receptors co-transfected in CHO cells. Biochem. Pharmacol. (1999) 58:1035-1045.
89. SALIM H, FERRE' S, DALAL A et al: Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells. J. Neurochem. (2000) 74:432-439.
90. SVENNINGSSON P, LINDSKOG M, LEDENT C et al.: Regulation of the phosphorylation of the dopamine and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2 and adenosine A2A receptors. Proc. Natl. Acad. Sci. USA (2000) 97:1856-1860.
91. ONGINI E, DIONISOTTI S, GESSI S, IRENIUS E, FREDHOLM BB: Comparison of CGS15943, ZM241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. (1999) 359:7-10.
92. RALEVIC V, BURNSTOCK G: Receptors for purine and pyrimidines. Pharmacol. Rev. (1998) 50:413-492.
93. FREDHOLM BB, BATTIG K, HOLMEN J, NEHLIG A, ZVARTAU EE: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. (1999) 51:83-133.
94. MONOPOLI A, CONTI A, ZOCCHI C et al: Pharmacology of the new selective A2A adenosine receptor agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine. Arzneimittel-Forschung/DrugRes. (1994) 44:1296-1304.
95. POUCHER SM, KEDDIE JR, SINGH P et al: The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2A selective adenosine receptor antagonist. Br. J. Pharmacol (1995) 115:1096-1102.
96. TURGEON SM, POLLACK AE, SCHUSHEIM L, FINK JS: Effects of selective A1 and A2A agonists on amphetamine-induced locomotion and c-fos in striatum and nucleus accumbens. Brain Res. (1996) 707:75-80.
97. EL YACOUBI M, LEDENT C, PARMENTIER M, COSTENTIN J, VAUGEOIS J: SCH58261 and ZM241385 differentially prevent the motor effects of CGS 21680 in mice: evidence for a functional 'atypical' adenosine A(2A) receptor. Eur.J. Pharmacol (2000) 401:63-67.
98. MANDHANE SN, CHOPDE CT, GHOSH AK: Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol (1997) 328:135-141.
99. MORELLI M, FENU S, PINNA A, DI CHIARA G: Adenosine A2A receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur J. Pharmacol (1994) 251:21-25.
100. GRONDIN R, BEDARD PJ, HADJ TAHAR A, GREGOIRE L, MORI A, KASE H: Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology (1999) 52:1673-1677.
101. KANDA T, JACKSON MJ, SMITH LA etal: Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian models. Ann. Neurol. (1998) 43:507-513.
102. ROBERTSON GS, TETZLAFF W, BEDARD A, ST-JEAN M, WIGLE N: c-fos mediated antipsychotic-induced neurotensin gene expression in rodent striatum. Neuroscience (1995) 67:325-344.
103. MARTIN GE, ROSSI DJ, JARVIS MF: Adenosine agonist reduced conditioned avoidance responding in the rat. Pharmacol. Biochem. Behav. (1993) 45:951-958.
104. KAFKA SH, CORBETT R: Selective A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur. J. Pharmacol. (1996) 295:263-268.
105. HAUBER W, KOCH M: Adenosine A2A receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. NeuroReport (1997) 8:1515-1518.
106. MORELLI M, PINNA A, WARDAS J, DI CHIARA G: Adenosine A2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience (1995) 67:49-55.
107. KOOB GF, LE MOAL M: Drug abuse: hedonic homeostatic dysregulation. Science (1997) 278:52-58.
108. FIORINO DF, PHILLIPS AG: Facilitation of sexual behaviour in male rats following D-amphetamine-induced behavioural sensitization. Psychopharma-cology (1999) 142:200-208.
109. SELF DW, NESTLER EJ: Molecular mechanisms of drug reinforcement and addiction. Ann. Rev. Neurosci. (1995) 18:463-495.
110. NIKODIJEVIC O, JACOBSON KA: Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol. Biochem. Behav. (1993) 44:199-216.
111. RIMONDINI R, FERRE' S, GIMENEZ-LLORT L, OGREN SO, FUXE K: Differential effects of adenosine A1 and A2 receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur. J. Pharmacol. (1998) 347:153-158.
112. CHEN JF, BEILSTEIN M, TURNER TJ et al.: Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors. Neuroscience (2000) 97:195-204.
113. SAHRAEI H, MOTAMEDI F, KHOSHBATEN A, ZARRIN-DAST MR: Adenosine A2 receptors inhibit morphine self-administration in rats. Eur. J. Pharmacol. (1999) 383:107-113.
114. BALDO BA, KOOB GF, MARKOU A: Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats. J. Neurosci. (1999) 19:11017-11026.
115. KAPLAN GB, SEARS MT: Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs. Psychopharmacology (1996) 123:64-70.
116. GREENGARD P, NAIM AC, GIRAULT JA et al.: The DARPP-32/protein phosphatase-1 cascade:amodel for signal integration. Brain Res. Brain Res. Rev. (1998) 26:274-284.
117. PORKKA-HEISKANEN T: Adenosine in sleep and wakefulness. Ann. Med. (1999) 31:125-129
118. SCHWIERIN B, BORBELY AA, TOBLER I: Effects of N6-cyclopentyladenosine and caffeine onsleep regulation in the rat. Eur. J. Pharmacol. (1996) 300:163-171.
119. MENDELSON W: Sleep-inducing effects of adenosine microinjections into the medial preoptic area are blocked by flumazenil. Brain Res. (2000) 852:479-481.
120. DUNWIDDIE TV, FREDHOLM BB: Adenosine A1 receptors inhibit adenylate cyclase activity and neurotrasmitter release and hyperpolarize pyramidal neurons in rat hippocampus. J. Pharmacol. Exp. Ther. (1989) 249:31-37.
121. FIEBICH BL, BIBER K, LIEB K et al.: Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2A-receptor. Glia (1996) 18:152-160.
122. MONOPOLI A, LOZZA G, FORLANI A, MATTAVELLI A, ONGINI E: Blockadeof adenosine A2A receptorsbySCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. NeuroReport (1998) 9:3955-3959.
123. STONE TW, BEHAN WMH: Adenosine receptors, kynurenines and neuroprotection. Drug Dev. Res. (2000) 50:15.
124. POPOLI P, PEZZOLA A, REGGIO R, MALCHIODI AF, FALCHI M: Adenosine A2A receptor blockade prevents EEG and motor abnormalities in a rat model of Huntington's disease. Drug Dev. Res. (2000) 50:69.
125. CHEN JF STAAL R, XU K, BEILSTEIN M, SONSALLA PK, SCHWARZSCHILD TH: Novel neuroprotection by adenosine A2A receptor inactivation in an animal model of Parkinson's disease. Drug Dev. Res. (2000) 50:71.
126. LIBERATORE GT, JACKSON-LEWIS V, VUKOSAVIC S et al.: Inducible nitric oxide synthase stimulates dopamin-ergic neurodegenerationinthe MPTP modelofParkin-son's disease. Nature Med. (1999) 5:1403-1409.
127. HIRSH EC, HUNOT S: Nitric oxide, glial cells and neuronal degeneration in parkinsonism. Trends Pharmacol. Sci. (2000) 21:163-165
128. ABBRACCHIO MP, CATTABENI F: Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative disease. Ann. NY Acad. Sci. (1999) 890:79-92.
129. GUIDETTI P, REDDY PH, TAGLE DA, SCHWAREZ R: Early kynurenergic impairment in Huntington's disease and in transgenic animal model. Neurosci. Lett. (2000) 283:233-235.
130. MCDONALD C, MURRAY RM: Early and late environmental risk factors for schizophrenia. Brain Res. Brain Res. Rev. (2000) 31:130-137.
131. IMPAGNATIELLO F, GUIDOTTI AR, PESOLD C et al.: A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. USA (1998) 95:15718-15723
132. BARONDES SH, ALBERTS BM, ANDREASEN NC et al: Workshop on schizophrenia. Proc. Natl. Acad. Sci. USA (1997) 94:1612-1614.
133. KYOSSEVA SV, ELBEIN AD, GRIFFIN WS, MRAK RE, LYON M, KARSON CN: Mitogen-activated protein kinases in schizophrenia. Biol. Psychiatry (1999) 46:689-696.
134. YAN Z, HSICH-WILSON L, FENG J et al.: Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nature Neurosci. (1999) 2:13-17.
135. IKEMOTO S, PANKSEPP J: The role of nucleus accumbens dopamine in motivated behaviour: a unifying interpretation with special reference to reward-seeking. Brain Res. Brain Res. Rev. (1999) 31:6-41.
136. RIVKEES SA, REPPERT SM: RFL9 encodes an A2b-adenosine receptor. Mol. Endocrinol. (1992) 6:1598-1604.
137. PIERCE KD, FURLONG TJ, SELBIE LA, SHINE J: Molecular cloning and expression of an adenosine A2b receptor from human brain. Biochem. Biophys. Res. Commun. (1992) 187:86-93.
138. MARQUART DL, WALKER LL, HEINEMANN S: Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J. Immunol. (1994) 152:4508-4515.
139. JACOBSON MA, JOHNSON RG, LUNEAU CJ, SALVATORE CA: Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene. Genomics (1995) 27:374-376.
140. PUFFINBARGER NK, HANSEN KR, RESTA R et al.: Productions and characterization of multiple antigenic peptide antibodies to the adenosine A2b receptor. Mol. Pharmacol. (1995) 47:1126-1132.
141. PALMER TM, STILES GL: Structure-function analysis of inhibitory adenosine receptor regulation. Neuropharmacology (1997) 36:1141-1141.
142. STEHLE JH, RIVKEES SA, LEE JJ, WEAVER DR, DEEDS JD, REPPERT SM: Molecular cloning and expression of the cDNAfor a novel A2-adenosine receptor subtype. Mol. Endocrinol. (1992) 6:384-393.
143. MOGUL DJ, ADAMS ME, FOX AP: Differential activation of adenosine receptors decreases N-type but potenti ates P-type Ca2+current in hippocampal CA3 neurons. Neuron (1993) 10:327-334.
144. KESSEY K, TROMMER BL, OVERSTREET LS, JI T, MOGUL DJ: A role for adenosine A2 receptors in the induction of long-term potentiation in the CA1 region of rat hippocampus. Brain Res. (1997) 756:184-190.
145. PEAKMAN MC, HILL SJ: Adenosine A2B-receptor-mediated cyclic AMP accumulation in primary rat astrocytes. Br. J. Pharmacol. (1994) 111:191-198.
146. YAKEL JL, WARREN RA, REPPERT SM, NORTH RA: Functional expression of adenosine A2B receptor in Xenopus oocytes. Mol. Pharmacol. (1993) 43:277-280.
147. FEOKTISTOV I, BIAGGIONI I: Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J. Clin. Invest. (1995) 96:1979-1986.
148. PHILLIS JW, SMITH-BARBOUR M, PERKINS LM, O'REGAN MH: Acetylcholine output from the ischemic rat cerebral cortex: effects of adenosine agonists. Brain Res. (1993) 613:337-340
149. PHILLIS JW, O'REGAN MH, PERKINS LM: Effect of adenosine receptor agonists on spontaneous and K(+)-evoked acetylcholine release from the in vivo rat cerebral cortex. Brain Res. (1993) 605:293-297.
150. OKADA M, MIZUNO K, KANEKO S: Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci. Lett. (1996) 21:53-56.
151. FORSYTHE P, ENNIS M: Adenosine, mast cells and asthma. Inflamm. Res. (1999) 48:301-307.
152. FEOKISTOV I, POLOSA R, HOLGATE ST, BAGGIONI I: Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol. Sci. (1998) 19:148-153.
153. MEYERHOF W, MULLER-BRECHLIN R, RICHTER D: Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermio-genesis. FEBS Lett. (1991) 284:155-160.
154. LINDEN J, TAYLOR HE, ROBEVA AS et al: Molecular cloning and functional expression of a sheep A3 adenosine receptorwith widespread tissue distribution. Mol. Pharmacol. (1993) 44:524-532.
155. SAJJADI FG, BOYLE DL, DOMINGO RC, FIRESTEIN GS: cDNA cloning and characterization of A3, an alternatively spliced rat A3 adenosine receptor variant. FEBS Lett. (1996) 382:125-129.
156. PALMER TM, BENOVIC JL, STILES GL: Molecular basis for subtype-specific desentization of inhibitory adenosine receptors. Analysis of chimeric A1-A3 adenosine receptor. J. Biol. Chem. (1996) 271:15272-15278.
157. DE M, AUSTIN KF, DUDLEY MW: Differential distribution of A3 receptor in rat brain. Soc. Neurosci. Abstr. (1993) 19:42.11.
158. JACOBSON KA, NIKODIJEVIC O, SHI D, GALLO-RODRIGUEZ C, OLAH ME, STILES GL, DALY JW: Arole for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. (1993) 336:57-60.
159. RIVKEES SA, THEVANANTHER S, HAO H: Are A3 adenosine receptor expressed in the brain? NeuroRe-port (2000) 11:1025-1030.
160. ZHOU QY, LI C, OLAH ME, JOHNSON RA, STILES GL, CIVELLI O: Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1992) 89:7432-7436.
161. ABBRACCHIO MP, BRAMBILLA R, CERUTI S et al.: G-protein-dependent activationofphospholipaseCby A3 adenosine receptors in rat brain. Mol. Pharmacol. (1995) 48:1038-1045.
162. BARALDI PG, CACCIARI B, ROMAGNOLI R et al.: A3 adenosine receptor ligands: history and perspectives. Med. Res. Rev. (2000) 20:103-128.
163. VON LUBITZ DK, LIN RC, POPIK P, CARTER MF, JACOBSON KA: Adenosine A3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. (1994) 263:59-67.
164. DUNWIDDIE TV, DIAO L, KIM HO, JIANG JL, JACOBSON KA: Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. J. Neurosci. (1997) 17:607-614.
165. JACOBSON KA, PARK KS, JIANG JL et al.: Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology (1997) 36:1157-1165.